More specifically, we found that patients who had higher SPP1 expression levels showed a lower response to cisplatin-based chemotherapy, which is also supported by previous evidence from the literature and research on other types of cancers, such as lung [181] and ovarian cancer [182]. This evidence concerns the gene SPP1 and ovarian cancer.